InflaRx NV (InflaRx NV) Short-Term Debt : $0.00 Mil (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is InflaRx NV Short-Term Debt?

InflaRx NV's Short-Term Debt for the quarter that ended in Dec. 2023 was $0.00 Mil.

InflaRx NV Short-Term Debt Historical Data

The historical data trend for InflaRx NV's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InflaRx NV Short-Term Debt Chart

InflaRx NV Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt

Get a 7-Day Free Trial

InflaRx NV Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Short-Term Debt	Get a 7-Day Free Trial															-	-	-	-	-

InflaRx NV Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

InflaRx NV Short-Term Debt Related Terms

Thank you for viewing the detailed overview of InflaRx NV's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

InflaRx NV (InflaRx NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InflaRx NV (NAS:IFRX) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

IF0:Germany IF0:Germany

Address

Winzerlaer Strasse 2, Jena, DEU, 07745

Website

https://www.inflarx.de

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.